Quell Therapeutics

Quell Therapeutics

ABOUT US

At Quell we seek to deliver truly innovative, life-changing therapies for our patients. Our vision as a company is to build a major global biopharmaceutical company bringing transformational and valued therapies for a range of autoimmune and inflammatory diseases, as well as preventing rejection in organ transplantation, based on modular engineered Tregs.

OUR COMPANY

Quell Therapeutics Ltd (“Quell”), the world leader in the development of engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, announced it has raised $156 million in an oversubscribed Series B financing. The financing round was co-led by Jeito Capital, Ridgeback Capital Investments, SV Health Investors and Fidelity Management & Research Company LLC with participation from founding investor Syncona. New investors include British Patient Capital through its Future Fund: Breakthrough program, Janus Henderson Investors, Monashee Investment Management, Point72 and funds managed by Tekla Capital Management LLC

Departments (2)
Offices (1)
2
open positions
2
hiring across
0
last 24 hours
0
remote listings
2  positions
Quell Therapeutics
Research Associate - Technical Development - 12months fixed term contract maternity cover
Quell Therapeutics
White City, London R&D 2d ago
Quell Therapeutics
Qualified UK and European Patent Attorney - Cell engineering, immunology and immunotherapy - part time 3 days a week, maternity cover 10 months
Quell Therapeutics
London Corporate 1w ago

Pick a job to read the details

Tap any role on the left — its description and apply link will open here.